International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

Vol. 37 No. 1 February 2023, pp. 298-315

Postmenopausal Osteoporosis

Literature Review

Maged Naser[1], Mohamed M. Nasr[2], Lamia H. Shehata[3]

[1] Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Ob/Gyn,

[2] King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery, Consultant Endoscopic Surgery,

[3] Department of Radiology, Care National Hospital, KSA of Radiology.

Abstract – Osteoporosis is a chronic condition, similar to heart disease, diabetes, or hypertension. A huge gap exists in the primary prevention of fractures, and studies show that an expected 80% to 90% of adults don't get proper osteoporosis managment even in the secondary prevention setting. Case finding strategies have been created and effective pharmacological mediations are accessible. This review tends to how ideal to utilize the pharmacological choices that anyone could hope to find for postmenopausal osteoporosis to give long lasting fracture protection in patients at high and extremely high risk of fracture. The advantage of osteoporosis treatments far outweighs the uncommon risks.

Keywords – Postmenopausal: Osteoporosis; Diphosphonates; Denosumab; Duration of therapy.

I. INTRODUCTION

Osteoporosis is a serious medical condition confronting many aged populations all over of the world. The numbers are sobering - to some extent half of all postmenopausal women will encounter fractures during their lifetime [1-3]. There are no symptoms preceding fracture yet bone mineral density (BMD) and other risk factors can be utilized to distinguish women before fractures [3]. Tragically, most women with osteoporosis, including the people who have previously had fractures, don't know that they have osteoporosis, and are not getting adequate treatment [4-6].The outcomes (pain, disability, deformation, and increased mortality) differ by the area and type of fracture. Besides, the proof of antifracture adequacy and ability to lessen the consequences of fracture differ extensively among agents endorsed for the treatment and prevention of osteoporosis. The purpose of this article is to portray the attributes and results of different osteoporotic fractures in postmenopausal women, and to sum up the proof for antifracture adequacy of different pharmacologic agents, explicitly as respects hip fracture and other serious results. The objective is to more readily perceive and treat patients at increased risk of fractures, in order to diminish the incidence of fractures and their consequences.

1. What is an osteoporotic fracture?

Bone continually goes through rebuilding to repair and replace existing bone tissue. In aging, how much bone tissue step by step declines and structural components are lost on the grounds that how much bone formed is not exactly that which is resorbed. The rate of bone loss is advanced by estrogen lack, immobilization, other systemic diseases, and certain medications, especially glucocorticoids. Osteoporosis is characterized as "a systemic progressive skeletal disease portrayed by low bone mass and microarchitectural deterioration of bone tissue, with an ensuing expansion in bone fragility and susceptibility to fracture" [7].Classical osteoporotic fractures incorporate those of the wrist, spine, hip, ribs, pelvis, and humerus, yet the risk of fracture is expanded at most considered skeletal sites. The fractures are frequently alluded to as fragility, atraumatic, non-traumatic, or non-violent. These terms all incorporate fractures which result from minor injury, (for example, the force related with a fall from

Corresponding Author: Maged Naser

standing to ground level, or less), that would generally not cause fractures among young healthy individuals. The term symptomatic fracture applies to any fracture related with pain or different symptoms. This is a significant distinction as numerous women with vertebral fractures don't report having pain (asymptomatic fractures). Once in a while, stress fractures happen among patients with osteoporosis, while repetitive loading (like walking) surpasses the strength of compromised bone. Now and again, most frequently vertebral fractures, there might be no conspicuous occasion - such fractures are in some cases called spontaneous. The demonstration of bending forward might be adequate to cause vertebral fractures in people with osteoporosis [8].

Interestingly, the term pathologic alludes to fractures that are related with a contributing reason other than osteoporosis, like local bone metastasis. The incidence of fractures increments all things considered skeletal sites with age [9]. One key to perceiving osteoporotic fractures is that the force included would normally not cause fractures in a young healthy individual, however does as such among the older (10). What's more, fractures at most skeletal locales among the older are related most frequently yet not solely with low BMD [11]. As a matter of fact, low BMD is likewise connected with expanded risk of fractures related with falling from greater than standing level, and other injury like stubbed toes (i.e., from injury not normally viewed as related with osteoporotic fractures) [11, 12].



Figure 1 - Schematic of the typical deterioration in function after a wrist (Colles'), clinically diagnosed vertebral, or hip fracture in comparison with that resulting from normal aging. The vertical axis shows a range from need for total care to optimal function. Wrist fractures are associated with a minimal decrease in function, and patients return almost to prefracture status. Patients with vertebral fractures regain less function. Hip fractures typically occur in persons frailer than the general population; patients must be hospitalized for care and postoperatively regain only 50% of function (from Johnell, 22)

1.1 Hip fractures

Something like 16% (roughly one out of six) of generally postmenopausal Caucasian women will encounter hip fractures [2, 13, 14]. The rate is lower by roughly half among Blacks and Asians, yet additionally differs extensively among countries in Europe [15-17]. Hip fracture rate increments exponentially with age; subsequently, roughly 50% of all hip breaks happen after age 80, and upgrades in future increment the frequency decisively [10]. Most (>90%) hip fractures are related with a fall, but treatment for osteoporosis can successfully diminish this risk. It is additionally upsetting that the occurrence of hip fracture is expanding regardless of the expansion in the aging populations, for unknown reasons [14, 18]. Hip fracture is the most serious consequence of osteoporosis and is very common among older women. One overview found that the yearly number of clinic bed-days filled by hip fracture among women aged 45 and older was more noteworthy than for myocardial infarction, breast cancer, chronic obstructive pulmonary disease, or diabetes [19]. Women with hip fractures are two to multiple times as prone to die in the subsequent year, contrasted with women without hip fractures [20, 21]. This expanded mortality might be partly connected with poorer health among women with hip fracture, yet it isn't obvious how much the hip fracture might be a precipitating event. Hip fracture frequently prompts significant physical debility, long term nursing care, and loss of independence (Fig. 1) [22]. For instance, one planned study revealed that just 15% of enduring hip fracture cases had the option to walk without help, and in excess of 9 out of 10 couldn't climb steps a half year after the fracture [20]. In another review, very nearly one out of 3 enduring patients was disabled, and 9 out of 10 couldn't walk outside freely when overviewed six years after their hip fracture. For comparison, the greater part of individuals without hip fractures had the option to walk outside six years after the fact, and less

than 2% were disabled [23]. Consequently, clearly treatments that can prevent or diminish these figures will be of extraordinary advantage.

1.2 Wrist fractures

The rate of wrist fractures increments not long after menopause and is more prominent than for hip breaks before age 65 [10]. Roughly one out of 6 Caucasian women will encounter a wrist fracture (13, 24). A few studies have assessed that 8 to 10% of wrist fracture patients are hospitalized, and one review found the extent expanded with age to 76% after age 85 (9, 25). Another, occasionally serious, result of wrist fractures is algodystrophy (reflex sympathetic dystrophy); the extent impacted was under 10% in many studies, yet has been accounted for to be basically as high as 30% (9).

1.3 Other non-spine fractures

Humerus and pelvis fractures are common among osteoporotic patients, and are related with severe acute symptoms and debility, however the degree and span of long-term outcomes have not been described. Numerous different fractures are additionally connected with osteoporosis, including those of the ribs, leg, hand, foot, and clavicle [11]. Subsequently, fractures other than the hip record for around 90% of short-term services connected with osteoporosis, and 4 out of 5 fracture related hospitalizations among the elderly [26]. On average, women who have had non-spine fractures are 2 to multiple times bound to report hardships with exercises of everyday living than those without fractures [23, 27]. Mortality may likewise be expanded among women with different non-hip fractures, including the spine [28, 29]. These supposed non-classical fractures are frequently not thought of or perceived as being connected with low BMD or osteoporosis and obviously, awareness should be increased.

1.4 Vertebral fractures

Vertebral fractures are the most widely recognized type of osteoporotic fracture; upwards of one out of 3 women will encounter vertebral fractures [24]. Spine radiographs are expected for the diagnosis of vertebral fractures, incompletely on the grounds that up to half of all patients with vertebral fractures don't report having symptoms (asymptomatic vertebral fractures). In any event, when present (symptomatic, or painful, vertebral fractures), symptoms are not adequately well defined for affirm a finding without radiographs. Besides, symptoms, for example, back pain are common among everybody, including women without vertebral fractures. Vertebral fractures distinguished on radiographs are frequently called radiographic (or morphometric) vertebral fractures; these incorporate fractures recognized unexpectedly (not because of examination of back pain). Epidemiologic studies and clinical preliminaries that screen all members have tracked down that only one-quarter to one third of all postmenopausal women with vertebral fractures recognized on radiographs have had clinical vertebral fractures, with symptoms extreme enough that the patient looked for clinical assistance, and examination prompted finding (some patients with symptoms either don't look for clinical care, or are not diagnosed) [30].

Overall, women who have had spine fractures are 2 to multiple times bound to report difficulties with activities of everyday living than those without fractures [27, 31, 32]. Patients with clinical vertebral fractures report more noteworthy pain and weakness than those whose fractures were not analyzed (morphometric fractures) [30, 33]. The greater part of women with new clinical vertebral fractures announced no less than 7 days of bed rest because of back pain, and over 90% detailed no less than 7 days of restricted movement because of back pain [33]. The extent of women who revealed at least 7 days of bed rest was two times as high among women with clinical vertebral fractures contrasted with those with morphometric vertebral fractures as it were. Different outcomes like back pain, and long periods of restricted action were additionally more prominent among women with clinical vertebral fractures contrasted with those with morphometric fractures. In any case, women with either fracture type had more extreme results than women without vertebral fractures. For instance, women with either type of vertebral had 28 times the risk of having no less than 7 days of bed rest because of back pain, contrasted with the fracture free period. The extent of women with symptoms, and the seriousness of symptoms increment with the number and seriousness of vertebral fractures [30-34]. Despite the fact that symptoms are many times not extreme enough to come to clinical consideration until various fractures happen, there are regular special cases - single vertebral fractures are once in a while agonizing. Intense symptoms of vertebral fracture range from mild to intolerable back pain, which might be limited, or diffuse [30]. Chronic pain might endure for quite a long time in certain patients; this might be connected with postural changes and burden on muscles and tendons because of changes in the shape and load distribution of the spine, or different causes which can in some cases be corrected [30, 35]. Among women with symptomatic vertebral fracture and ongoing pain, 60 to 87% detailed issues with conveying, lifting, strolling,

housework, and shopping [36]. Like hip fractures, clinical vertebral fractures are additionally connected with expanded mortality (2, 28, 37).

The intense symptoms from vertebral fractures frequently resolve in something like 2 months and can frequently be made do with analgesics and a brief time of bed rest [30, 35]. Patients ought to continue activities at the earliest opportunity, and breaking point bed rest to limit extra deficiency of bone density, muscle strength, and endurance. For patients with serious pain, hospitalization has been suggested, except if sufficient help is accessible at home [35]. Vertebral fractures seem to represent most loss of level in more elder women. One epidemiological review revealed that women with new vertebral fractures lost a normal of 2 cm in level, while the typical level average among different women was just 0.4 cm over of an 8-year time span [38]. Height loss expanded with respect to the number of fractures - a normal of 1 cm for each fractured vertebra. It is entirely expected for women with vertebral fractures to lose 4 cm (2 inches) in height [34].

Quality of life envelops physical debility, yet in addition psychosocial viewpoints, for example, anxiety toward fractures, anxiety toward impedance, diminished capacity to take part in family/social events, and worries about appearance (like spinal distortion and height loss) that might bring down confidence [30, 39, 40]. For instance, back pain and back weakness decrease the period of time an individual can sit or stand; this can restrict support in church events, theatre, and so on. Apprehension about falls and extra fractures may likewise prompt decreases in actual work. This speeds up decreases in bone density, muscle mass, and endurance, further expanding the risk of fractures. Medical services costs. There are in excess of 250000 hip fracture cases every year in the US, bringing about roughly 3.4 million medical clinic bed days, >7 million days of confined movement, and 60000 nursing home admissions [26, 41]. On average, addressing around 63% of fracture related expenditure [22]. Evaluations of the yearly medical care costs for osteoporotic fractures range from $6 billion to $20 billion in the US alone [42]. These figures don't consider extra care and support given by family or different sources. In this manner, while non-hip fractures address an enormous cost in suffering and medical services costs, most of medical care expenditure because of osteoporosis are connected with hip fractures, and hip fracture greatly affects an individual's wellbeing than some other single type of fracture. With respect to physical deblity, one could contend that asymptomatic vertebral fractures are of minimal clinical result, then again, actually they signal expanded hazard of future fractures, including more serious hip fractures, and mortality.

2. Who is ought to be treated?

Obviously osteoporotic fractures influence half of postmenopausal Caucasian women over their lifetime, and the outcomes are frequently destroying. Hence, the National Osteoporosis Foundation (NOF) and others suggest that skeletal health be assessed at each office visit, and that osteoporosis ought to be considered as seriously, and treated as aggressivlly, as hypertension [43, 44].Be that as it may, not all women will be impacted - how might you recognize those at risk? fracture risk is in many cases assessed utilizing BMD "T-scores" (Figure 2). The T-score expresses the patient's BMD as the number of standard deviations (SD) below the mean for young women; negative values address BMD below average for young women. The lower range for young healthy women (2 SD below the mean) relates to a Tscore of - 2.0 [44]. It is vital to perceive that hazard increments dynamically with declining BMD values; a T- score o f - 4.0, hence, demonstrates a lot more prominent fracture risk than a T-score of - 2.0 [45-47].



Figure 2 (T-score)

Bone density varies broadly among people, and BMD estimations can distinguish large differences (no less than ten to twenty-fold) in risk among women of comparable age (3). Also, BMD declines with age, so that half of women aged 70-79 years have femoral neck BMD T-scores less than - 2.0, and the extent increments to roughly 70% of women aged 80 years and older [48]. Whenever the situation allows, all women aged 65 and older ought to have BMD measurements [44]. Risk factors other than BMD are likewise significant. Suspect osteoporosis in any postmenopausal women with a new fracture (or a background marked by fracture after menopause) from low to moderate trauma. Women who have had an earlier fracture (of any kind) are roughly two times as logical as different women to encounter extra fractures at any skeletal site [49]. Specifically, women with an earlier vertebral fracture have multiple times the risk of ensuing vertebral fractures, contrasted with different women, and the risk increments with the number of past fractures [47, 50, 51]. Considering the aftereffects of cost-effective analysis, the NOF suggests considering treatment for women who present with vertebral or hip fractures, and those with BMD T-scores < - 2.0, to bring down the risk of subsequent fractures ensuing fractures. Likewise, consider treatment for women with BMD T-scores < - 1.5 assuming they have at least one extra risk factors [44].

A large prospective review (N=52050) revealed that women who meet the NOF rules have a higher risk of fractures than other women [52]. Women older than 70 years with multiple risk factors (particularly those with a past fracture) are at sufficiently high risk to justify treatment without measuring BMD, despite the fact that estimating BMD is desirable to evaluate the level of chance and possibly to provide a baseline from which to pass judgment on the efficiency of treatment [44].It ought to be perceived that the above are guidelines only, and don't hinder the requirement for the physician to choose proper stratigies for a particular patient. Assuming one is just worried about fractures in the short term, for example, the following 5 years, then treatment may be restricted to postmenopausal women who have proactively had a fracture and women with very low BMD (T-score < - 2.5), in light of the fact that such women have a high outright risk of fractures during the following 5-10 years. fracture risk is more noteworthy for more established women than for more young women with comparable BMD values [3]. Hence, more older women (age > 65 years) with low BMD (T < - 2.0) could likewise be treated with. While younger women (age <65 years) will have a lower fracture risk over a shorter period of time than more older women with a similar BMD, the long-term risk will be more prominent for the younger women for two reasons. In the first place, BMD will keep on declining, so they will have lower BMD (and higher risk) when they arrive at the more established age. Second, their fracture risk will have expanded with age (regardless of whether BMD were to stay consistent, which it probably will not). Accordingly, the physician ought to consider the expected present moment and long-term advantages and risks of treatment for every individual patient prior to starting treatment. At present, most women with recent fractures are not being treated. A new study revealed that just 39% of women determined to have vertebral fractures were utilizing prescriptions to lessen fracture risk a year later. The extent was even lower among women with hip or wrist fractures - simply 4 to 5% were utilizing drugs to decrease fracture risk a year later [4, 5]. Among age-matched controls, the extent utilizing such drugs went from 2 to 6% during a similar period. One review revealed that densitometry is frequently not utilized for patient assessment in any event, when it is free [53]. Clearly, on the proportion that the extent of high-risk patients being dealt with is this low, we should grow our efforts incredibly. Education decisively increments patient responsiveness to intervention, so among those with late fractures [54].

3. Adequate Medicines

Adequacy is exhibited best in randomized, placebo-controlled clinical preliminaries [55-57]. Observational studies (like community or epidemiologic studies) can give supporting proof, however, are dependent upon numerous possible sources of bias, and are not so solid as randomized preliminaries. Choosing an agent can be directed by three proof-based measures of expanding significance: 1) increases in BMD, 2) decreases in fracture risk, and 3) decreases in serious health consequences of fractures [55, 56]. Preliminaries of osteoporosis prevention (treatment to prevent bone loss in women who don't have osteoporosis), albeit critical, won't be discussed here, on the grounds that BMD and not fracture was the primary endpoint in anticipation preliminaries [57].

3.1 Increase in BMD

Expanding BMD is a significant marker that might reflect enhancements in bone strength when typical bone histology is maintained. Expansions in BMD would in general be bigger in preliminaries of alendronate, fluoride, and estrogen. Bigger expansions in BMD during alendronate treatment are related with lower rate of fracture [58]. Be that as it may, BMD is a surrogate result, and isn't adequate proof without help from anyone else to ensure antifracture effeciency. For instance, fluoride

treatment has been displayed to expand BMD considerably, yet has not been displayed to prevent fractures, maybe on the grounds that the recently shaped bone is unusual [59]. In this way, BMD changes are not discussed further here.

3.2 Antifracture efficacy

Accordingly, the second degree of proof, antifracture efficacy, is fundamental while thinking about treatment choices, on the grounds that BMD data alone might misdirect. A much more powerful element while considering treatment choices is the third degree of proof - that the agent can decrease the risk of fracture sequelae which are vital to the well-being (lifestyle) of the patient. Without direct proof of decreases in results of fractures (disability ,pain, quality of life, and so forth), inclination ought to be given to agents that have been displayed to lessen the risk of fractures associated with serious results, for example, hip and clinical spine fractures, as a decrease in morphometric vertebral fractures alone isn't adequate to ensure efficacy as to different types of fractures or related outcomes [55, 56]. The favored technique for summing up proof is by a systematic review [55]. Such an audit ought to incorporate a comprehensive review of the literature and supporting information, express criteria for consideration of reports that are recognized, and unequivocal models for rating and summing up the findings. One ongoing report utilized this methodology [57].

To qualify as sufficient proof of antifracture efficacy, each study needed to have:1) fracture as a pre-specified, primary endpoint; 2) randomized, double-blinded plan; 3) fundamentally decreased risk in view of patients with new fractures (not total number of new fracture); and 4) steady outcomes in the event that few preliminaries were performed. Moreover, preference was given to peer-surveyed, published findings. It is essential to determine fracture as the primary endpoint before conducting a preliminary, on the grounds that stistically large decreases in risk might happen because of chance alone in post-hoc examinations, particularly in preliminaries with small sample sizes [55, 56]. Large preliminaries and predictable outcomes in more than one review give more noteworthy trust in the discoveries for a specific agent .In light of the prior measures, the proof was viewed as uncertain for some agents that have been analyzed, partly in light of the fact that randomized preliminaries of sufficient size have not been performed for these agents. Albeit 35 preliminaries were recognized through October 1998, Meunier [57] reasoned that main two met the five standards expressed over; one investigation of alendronate [60], and one of vitamin D in addition to calcium (albeit the last option was led in a populace in risk of a specific type of fracture, i.e., from subclinical vitamin D lack) [61]. Extra information showing antifracture efficacy have now been accounted for two different agents - raloxifene and risedronate [62-64].

A large preliminary of raloxifene (N=7705) got follow-up spine radiographs for 89% of members [62]. A large 30% decrease in the frequency of radiographic vertebral fractures was noticed for women randomized to raloxifene 60 mg daily, the recommended dose. Be that as it may, there was no significant impact on the frequency of in general non-vertebral fracture or hip fractures. Two large preliminaries (N=2458 and 1226, separately) announced large decreases in vertebral fracture occurrence for risedronate 5 mg daily versus placebo treatment [63, 64]. Albeit these studies announced risk decreases of 41-49%, the risk decreases were only 31-36% when limited to the primary endpoint (all occurrence vertebral fractures) and determined involving a similar methodology as the alendronate FIT preliminary [60, 65]. These studies of risedronate likewise detailed decreases of 33-39% in the incidence of certain non-spine fractures (clavicle, humerus, wrist, pelvis, hip, or leg). In spite of the enormous combined sample size, there was no impact on hip fractures occurrence in these two preliminaries [65]. A third large preliminary of risedronate (N=9497) revealed an overall 24% decrease in the incidence of hip fracture [66]. In this manner, the impact on hip fracture was not steady across preliminaries and joining the consequences of every one of the 3 preliminaries would yield a typical risk decrease of under 24% for hip fractures. Moreover, an extremely high loss to follow-up (~50%) in the risedronate preliminaries lessens confidence in the findings [67].

For alendronate, the large fracture Intervention Preliminary (FIT) revealed steady decreases in the incidence of all types of fractures. The occurrence of hip fractures, clinical vertebral fractures, wrist fractures, and new morphometric vertebral fractures was diminished by roughly half among women with earlier vertebral fractures [62]. Practically all (98%) of the surviving women completed the preliminary. Different studies have affirmed these findings in women with osteoporosis as characterized by BMD, with orwithout earlier vertebral fractures [68-70]. The FIT additionally detailed that women randomized to alendronate had significantly lower risk of results that are critical to patients - long periods of bed rest and limited activity because of back pain [33]. Different analyses propose that the rate of hospitalization may likewise be lower among women randomized to alendronate [71]. A new preliminary revealed that giving alendronate at a higher dose (70 mg) when seven days gives a similar efficiency as

the 10 mg daily regimen [72]. The lower frequency of administration ought to be more helpful for patients; this weekly dosing routine has previously been endorsed in certain countries and may before long be accessible in others.

One review revealed a large decrease in risk of hip and non-vertebral fractures among women randomized to vitamin D in addition to calcium [61]. In any case, the 27% decrease in hip fracture rate was exclusively about half of that detailed for alendronate (51% decrease) and was not affirmed in a separate study. The impact on vertebral fracture frequency was not assessed. The review populace comprised of women with a high prevalence (roughly 50%) of vitamin D inadequacy and low calcium consumption (mean 511 mg/day). A subsequent study of vitamin D supplementation of women and men with mean calcium intake of 868 mg/day tracked down no impact on the frequency of hip or non-spine fractures; as a matter of fact, the rate was higher in the treatment group, but not essentially different. Consequently, apparently the advantage of vitamin D in addition to calcium might be restricted to the people who are vitamin D deficient [73]. There is some extra proof from preliminaries that didn't fulfil of the standards expressed previously. A small study of calcium in addition to vitamin D revealed a large reduction in the occurrence of non-vertebral fractures [74]; in any case, fracture was not a pre-specified endpoint, and close to 33% of the fractures happened at skeletal sites (face, lower leg, foot) that are not typical of osteoporosis [11]. For morphometric vertebral fractures, there is some proof of antifracture adequacy from moderately small preliminaries of calcium monotherapy, estrogen, etidronate, and calcitonin, yet the outcomes were either not measurably large, or neglected to meet other important criteria [57]. Proof of a decrease in non-vertebral fractures occurrence is lacking for these agents.

In large numbers of the randomized, controlled studies, all participants (counting the control group) got calcium supplements and adequate vitamin D. Hence, the findings address impacts far in excess of those of calcium and vitamin D alone. Guaranteeing satisfactory calcium and vitamin D intake, and sufficient activity levels, is important [44]. Nonetheless, calcium, vitamin D, and exercise alone are not adequate for some women, who need treatment with additional potent agents .Consequently, with regards to getting osteoporosis lessen fracture risk, the bisphosphonates, alendronate and risedronate, have the most persuading proof regarding viability concerning expanding bone density and diminishing the risk of fractures. The proof is fairly more persuading for alendronate, particularly as to impacts on hip fractures and the consequences of fractures. For prevention, selection of treatment might be affected by different variables, for example, the potential therapy benefits or risks related with breast malignant growth, heart disease, and other results; these issues are past the extent of the ongoing article. While treating with any agent, the physician ought to know about the indications, dosing, instructions, and prescribing precautionary measures [44,75].

4. How long should treatment proceed?

There is moderately little data in regard to the benefits and risks of long-term treatment from clinical preliminaries. Fast decreases in BMD and increases in biochemical markers of bone turnover happen after discontinuing estrogen, like early post menopause. Conversely, bisphosphonates persevere in bone for a really long time, and may keep on supressing bone turnover somewhat (however not completely) after stopping treatment [76]. For instance, biochemical markers increment gradually after discounting alendronate. Albeit quick decreases in BMD don't happen after stopping alendronate, the skeletal benefits might be more prominent if the treatment is proceeded, as estimated by expansions in BMD and decreases in biochemical markers of turnover [77].

One study of dogs utilizing multiple times the standard human dose of risedronate, and alendronate proposed that excessive inhibition of bone turnover could impair bone strength [78]. Nonetheless, the relevance to human is obscure, on the grounds that this study didn't utilize a high-turnover osteoporosis model, and curiously high dosages were utilized. In an ovariectomized monkey model of high turnover, alendronate decreased turnover to control (non-ovariectomized) levels or lower, and expanded BMD, bringing about an expansion in bone strength [79]. Among patients treated with alendronate, bone turnover markers return to within the premenopausal range, and are not excessively suppressed. In this way, kept checking of long-term safety is prudent, however existing proof demonstrates that there is a significantly wide safety margin of diminished bone turnover, and that the risk of osteoporotic fractures is decreased, not expanded [80]. A few women in clinical preliminaries have utilized alendronate continuously for something like 7 years; despite the fact that it was not viewed as moral to keep a simultaneous fake treatment bunch for quite a long time, there is no proof of an expansion in fracture risk over the long run among long term alendronate users [77]. Consequently, five to seven years of treatment are probably going to be safe [76].

5. The requirement for Activity

To have an effect on this disease, skeletal health ought to be considered at every office visit; osteoporosis ought to be viewed as seriously, and treated as aggressively as hypertension [43, 44]. Albeit the short term (yearly) risk of fracture is low for most women, the long-term risks are high, and the greater part of postmenopausal women will encounter fractures. For the overwhelming majority postmenopausal fractures younger than age 70, spine fractures are frequently seen by patients as a more prominent risk in light of the possible impacts on appearance. In any case, hip fractures have more serious outcomes, including loss of independence, which is many times a main issue of older patients. We ought to know that wrist and different fractures are frequently not seen by patients and physicians as a consequence of osteoporosis, since they are normally associated with falls. Patients ought to be advised that wrist and spine fractures generally happen sooner than hip fractures among women with osteoporosis and are many times an early indication of osteoporosis and expanded fracture risk, yet that hip fractures are the most serious outcome of osteoporosis. Patients at high risk (the people who have proactively had fractures, and those with exceptionally low BMD or numerous risk factors) should be dealt with aggressively. Reliably, solid proof from clinical preliminaries exhibits that alendronate decreases the risk of hip fracture, vertebral fracture (including clinical fractures), hospitalization, long periods of bed rest because of back pain, and long periods of restricted movement because of back pain. The decrease in chance of vertebral fractures turns out as expected in any event, for women with low BMD (T-scores < - 1.6) who don't meet the criteria for osteoporosis. Risedronate is likewise an effective agent for decreasing the risk of both vertebral and non-vertebral fractures, while raloxifene has been displayed to diminish the risk of vertebral fractures, however not non-vertebral fractures. There is likewise proof that, among patients with low calcium intake, expanding vitamin D and calcium can assist with preventing hip fractures, despite the fact that apparently this advantage is not exactly for alendronate, and might be increased by adding alendronate. The outcomes from studies of most different agents are either still underway, or uncertain [68].

6. A once yearly intravenous bisphosphonate

Bisphosphonates (alendronate and risedronate) have turned into the pillar of osteoporosis treatment in both men and women. In any case, administration of these medications, which have poor oral bioavailability and periodically cause oesophageal irritation, can be cumbersome, prompting poor compliance. What's more, a few patients have been not able to take oral bisphosphonate treatment in view of esophagitis, inflammatory bowel disease, or on the grounds that they are at bed rest. For these patients pamidronate, an infusible bisphosphonate allowed every 3months, has been a treatment alternative, yet isn't Food and Drug Administration (FDA) supported for these indications. A new and stronger aminobisphosphonate, zoledronic acid, fundamentally further improves BMD when infused only one time a year.

Intravenous zoledronic acid in postmenopausal women with low bone thickness. (N Engl J Prescription, 2002). This was a randomized, placebo-controlled, dose ranging preliminary 4 regimens of zoledronic acid (0.25 mg or 0.5 mg or 1 mg intravenous every 3months, 2 mg two times a year, or 4 mg intravenous one time a year) in 351 postmenopausal women with low bone mass. At a year, the joined zoledronic acid groups had a 5% and 2.5 % increment in lumbar spine and femoral neck BMD, respectively, and there was no significant difference in the impact of the 3months versus once every year regimen .This study was not powered to analyse fracture prevention and was not sufficiently long to resolve that issue. Adverse events were more common in the treatment groups (45-67% versus 27% in the placebo group) and comprised of musclo skeletal pain, nausea, and fever. The authors express that the majority of the toxicity happened with the first dose, the number of side effects throughout the year was not different in the different dose groups, and that withdrawals for toxicity were not different by dose. The authors don't state whether the toxicity with the first infusion was dose dependant [81].

Zoledronic acid is as of now accessible for the adjuvant treatment of metastatic bone disease and is in clinical preliminaries currently tending to fracture prevention. If zoledronic acid is found to essentially diminish the risk of fractures when infused one time per year, it will be an alternative treatment for patients who need an intravenous bisphosphonate and for patients who can't agree with oral bisphosphonate treatment. This might be an especially engaging treatment for hospitalized fracture patients to prevent further bone loss during immobilization and rehabilitation, and for hospitalized patients going to start long term, high-dose glucocorticoid treatment who could experience difficulty complying to oral bisphosphonate regimens.

7. Availability of an agent to stimulate bone formation

Until recently, all the FDA-approved medicines available to prevent osteoporotic fractures were antiresorptive agents that had restricted ability to increment bone density. Teriparatide (PTH) is the first agent that stimulates bone formation and has been

displayed to diminish fracture risk. Impact of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women (N Engl J Prescription, 2001) [82]. In an 18-month placebo treatment controlled preliminary, 1,637 postmenopausal women with an earlier vertebral fracture were randomly relegated to treatment with 20 or 40 g/ml of parathyroid hormone (teriparatide) by daily subcutaneous injection. New nonvertebral fractures happened in 6% of placebo treatment patients and 3% of those in the parathyroid hormonal gathering (relative risk [RR] 0.47). The distinction in BMD between the treated and placebo treatment patients was 9% and 13% in the lumbar spine, and 3% and 6% in the femoral neck in the 20 g/ml and 40 g/ml groups respectively. Complete body BMD expanded 2% and 4%, respectively. One vertebral fracture was prevented for every 12years of treatment with the 20 g/ml dose (FDA-supported dose) at an expense of $96,000 per fracture avoided. New or deteriorating back pain was accounted for in 23% of the placebo treatment group and 17% of the 20 g/ml group. The review was not controlled to evaluate a distinction in femoral fracture rates. Nausea, headache, dizziness, leg cramps, and expanded urinary calcium were more in the PTH group. Mild hypercalcemia happened in 2% of women in the placebo treatment group and 11% of those in the 20 g/ml group. The review was stopped prematurely by the sponsor since bone tumours created in Fischer 344 rodents during a long-term toxicology study. Teriparatide ought not be given to those with a higher risk of osteosarcoma like those with Paget's disease, history of skeletal radiation, or children with open epiphysis. The impacts of tereparatide on bone density following year and a half are unknown.

Two studies discovered that adding alendronate to teriparatide doesn't greaterly affect bone density than treatment with teriparatide alone [83,84]. A study in 437 osteoporotic men exhibited an increment of 5.9% and 1.5% in lumbar spine and femoral neck bone density over of 11 months [85].Studies are continuous to decide the impacts of teriparatide on BMD after treatment is ceased and whether utilization of an antiresorptive agent after end of teriparatide treatment assists to sustain its consequences for BMD. The place of teriparatide in the treatment of osteoporosis and osteoporotic fractures is as yet unclear. Given the significant expense ($516 each month [86], everyday subcutaneous administration, and unknown long term impacts, it will in all probability be utilized to treat patients who have severe osteoporosis or keep on encountering fractures notwithstanding treatment with bisphosphonates or those patients with contraindications to or toxicity from bisphosphonates.

Update on the role of estrogen in the treatment of osteoporosis: the risks and benefits of estrogen replacement from the Heart and Estrogen/Progestrin Substitution Study (HERS) and Women' health Initiative (WHI) studies For quite a long time, the utilization of hormonal replacement treatment (HRT) was legitimate based on epidemiologic information that exhibited a lower rate of coronary disease in HRT users and prospective studies that showed valuable consequences for lipid profiles. Also, HRT use is related with higher BMD and lower fracture rates. The accepted cardiovascular advantages offset the more modest expanded hazard of breast disease and thrombosis. Be that as it may, the prospective HERS II and WHI preliminaries showed no cardiovascular advantages of conjugated equine estrogen (CEE) with medroxyprogesterone (MPA) and prompted a re-evaluation of the role of estrogens in the counteraction and treatment of osteoporosis .Risks and benefits of estrogen in addition to progestin in healthy postmenopausal women: chief outcomes from the WHI randomized controlled preliminary. (JAMA, 2002) [87]. This part of the WHI was a randomized, placebo treatment controlled preliminary of 0.625 mg/day of CEE and 2.5 mg/day of MPA versus placebo treatment on occurrence of coronary heart disease (CHD) and invasive breast cancer in 16,608 healthy postmenopausal women over a time of 5 years. The relative risks of cardiovascular disease, stroke, and breast cancer were expanded (1.29, 1.44, and 1.26 separately) yet the overall risk of hip fractures fracture and colorectal cancer was diminished to 0.66 and 0.63, respectively. The relative risk of cancer was 1.03 and the risk of mortality was 0.98. This study affirmed an expanded risk of breast cancer and the protective impacts of estrogen on fractures.

Absolute risk per 10,000 persons years of exposure were 7 more CHD occasions, 8 additional strokes, 8 additional pulmonary embolisms (PEs), 8 more breast cancer, 5 less hip fractures, and 6 less colorectal tumours. The time pattern analysis showed that the protective impacts from colorectal cancer happened following 3 years of treatment and was seen consistently through the 5 years for hip fracture. An expanded risk of stroke arose following one year, however the expanded risk for CHD and PE was seen not long after randomization. The absolute expansion in risk of breast cancer went from 0.2% each year in non-HRT users to 0.3% each year in HRT users. Cardiovascular disease results during 6.8 years of hormonal treatment: Heart and Estrogen/Progestin Replacement Study follow up (HERS II). (JAMA, 2002) [88]. HERS I was a 4.1-year randomized, double-blind, placebo treatment-controlled study of the impacts of 0.625 mg of CEE and 2.5 mg of MPA on cardiovascular events in postmenopausal women with coronary artery disease. HERS II was the 2.7year open label study of the HERS I study and 2,321 of the 2,763 women who participated in HERS I. The decision to proceed or begin HRT was left to the doctor and patient, and 81%

of those patients initially assigned to HRT proceeded with that treatment toward the end of year 1 and 45% toward the end of year 6. Following a total of 6.8 years of study, HRT didn't diminish the risk of cardiovascular events in this high-risk group of women.

Noncardiac disease results during 6.8 years of hormonal treatment: Heart and Estrogen/Progestin Replacement Study follow up (HERS II). (JAMA, 2002) [89]. This article tended to noncardiovascular events in the HERS review and tracked down no distinction in the risk of any fracture (RR 1.04, 95% confidence interval [95% CI] 0.87-1.25) in the hormone replacement versus the fake treatment bunch. The RR for any malignant growth was not essentially expanded (RR 1.19, 95% CI 0.95-1.50), the relative risk of biliary disease and thromboembolic disease was expanded to 1.48 (95% CI 1.12-1.95) and 1.40 (95% CI 0.64-3.05), respectively. The WHI and HERS review tracked down no protective impact of combination HRT against cardiovascular disease or recurrent cardiovascular events in postmenopausal women. The WHI study showed that HRT diminished hip fracture risk yet this was not shown in the HERS II preliminary. Be that as it may, the WHI included more than 16,000 women while HERS II included just 2,321 women and was not powered to evaluate hip fracture differences. The total risk and benefits of HRT versus no HRT are extremely close in terms of overall cancer risk and mortality in the WHI study. Albeit no general health advantage was seen from treatment with this dose of conjugated estrogen and progesterone, the role of lower dose estrogen or a similar dose of estrogen without progesterone is still under study. The arm of the WHI study tending to risk and benefits of estrogen without progesterone is progressing. The accompanying article tends to the potential benefits of lower doses of estrogen on bone density.

Impacts of lower dosages of formed equine estrogen with and without medroxyprogesterone acetic acid derivation on bone in early postmenopausal women. (JAMA, 2002) [90]. In this review, 822 healthy postmenopausal women within 4 years of their last period (early menopause) were randomized to get different dosages of estrogen (CEE) (0.625, 0.45, 0.3 mg/day) regardless of progesterone (MPA) for quite some time. In this review, a dose impact was shown, the 0.625 md dose of CEE greaterly affected spine BMD than the 0.3 mg/day dose. The impacts of MPA on improvement in BMD were just seen in lumbar spine BMD and were just large at the higher dose of estrogen (0.625 mg). The 0.3-mg dose of CEE was related with stable BMD in the lumbar spine. Lower estrogen doses, which are frequently sufficient to control vasomotor symptoms and have less of a negative impact on coagulation factors and endometrial hyperplasia, may also help maintain lumbar spine BMD, according to this study. Recker et al.'s [91], low-dose continuous estrogen and progesterone therapy with calcium and vitamin D preserved bone density in elderly women, which is supported by this study.

8. Individualized long term pharmacological therapies

Experts have proposed a "treat-to-target" strategy, in which a specific goal for long-term fracture prevention (like a total hip T-score between –2 and –1.5) is established [92], and therapy is individualized and periodically re-evaluated based on this goal [93]. In the past, BPs were the first line of treatment for osteoporosis, and when they didn't work or after years of use, physicians would think about switching to another one. In treat-to-target, physicians select the drug or series of drugs most likely to achieve the target within a predetermined time frame, which may be short (one to two years for patients at imminent risk of fracture) or long (10 years for patients at high risk of fracture) [94]. It is essential to keep in mind that patients cannot stop receiving therapy if this goal is achieved. Bouxsein and others conducted a meta-regression analysis of the clinical trials of all pharmacological therapies that are commercially available. [95] demonstrated a strong correlation between an increase in BMD and a decrease in hip and vertebral fractures. This suggests that the risk of fracture can be measured using BMD as both a target and a substitute endpoint. According to the guidelines issued by the Endocrine Society, there is insufficient evidence to support any recommendation regarding the length of therapy [96]. However, the guidelines also state that postmenopausal women with a high fracture risk should continue their BP therapy even after three to five years if they continue to be at risk. Patients who stopped taking BPs were found to have a 20% to 40% higher risk of new clinical fractures and a nearly doubled risk of vertebral fracture when compared to those who continued taking BPs, according to a systematic review [97]. This indicates that "drug holidays" might not be safe for all BP patients. Osteoporosis should be treated in the same way that diabetes and high blood pressure are treated for long periods of time, despite the lack of long-term evidence.

8.1 Risedronate

During the extension of the Vertebral Efficacy with Risedronate Therapy-Multinational (VERT-MN) study, patients received either risedronate for seven years (n = 31) or a placebo for five years (n = 30), with risedronate being administered for two years. Neither group went to therapy in the eighth year. Total hip and femoral trochanter BMD decreased in the 2-year

risedronate group and increased toward baseline in the 7-year risedronate group, respectively. Nevertheless, there was no increase in the likelihood of a subsequent vertebral fracture [98]. Due to the small number of patients in each group, it is difficult to draw any conclusions from these findings, with the exception of the finding that there is no residual effect on BMD after one year off therapy [98].

8.2 Alendronate

The Fracture Intervention Trial's Long-Term Extension of Alendronate (FLEX; postmenopausal women who had been taking alendronate daily for a mean of five years either stopped taking it (n=428) or continued taking it for another five years (n=643) (an extension of the FIT trial). Gains in hip BMD slowed down after three years on alendronate. In women who stopped receiving treatment, BMD and BTMs gradually decreased and increased, eventually reaching levels that were comparable to the hip BMD at baseline five years later [99]. The risk of clinically recognized vertebral fractures was significantly lower in the group who continued taking alendronate (5.3% vs. 2.4%; a relative risk of 0.45; Alendronate continued use did not, however, provide any additional protection against nonvertebral fractures (95 percent confidence interval, 0.24–0.85).

8.3 Zoledronic acid

After three years of treatment, postmenopausal women were randomly assigned to receive either zoledronic acid or placebo in the six-year extension of the Health Outcomes and Reduced Incidence with Zoledronic acid once Yearly Pivotal Fracture Trial (HORIZON-PFT) [100]. In the group that continued to take zoledronic acid, femoral neck and hip BMD plateaued and remained stable after the first three years. BTMs and BMD remained constant in the zoledronic acid group, while the placebo group's BTMs and BMD trended toward pre-treatment levels. Additionally, there were significantly more new morphometric vertebral fractures in the placebo group (30 vs. 14, P=0.035). However, continuing therapy did not provide any additional protection against nonvertebral fractures [100]. Patients who had been taking zoledronic acid for six years were randomly assigned to continue treatment for three years (n=95) or switch to placebo (n=95), despite the much smaller number of patients in the 9-year extension [101].In the HORIZON Recurrent Fracture Trial [102], Zoledronic acid had a 28% lower risk of death from any cause than placebo (P=0.01) in patients who began therapy within 90 days of hip fracture surgery. This demonstrates that osteoporosis treatment reduces mortality. After an initial increase in BMD with BPs, particularly for BMD in the hip and femoral neck, a plateau is reached after two to three years of treatment [99,101].

Physicians didn't see a long-term benefit, which may have led to BP "drug holidays" being common. However, the increase in vertebral fractures observed in patients who discontinued these treatments in comparison to those who did not may be attributed to the fact that long-term use of alendronate [99] and zoledronic acid [49] results in an ongoing improvement in spine BMD. The American Society of Bone and Mineral Research Task Force recommended re-evaluating the 10-year fracture risk after 5 years of oral BPs or 3 years of intravenous BPs [103]. Keep in mind that "re-evaluate" does not always mean "discontinue." Women can safely switch from BP to DMAb, and high-risk patients need to be treated with either BPs or DMAb for a long time [104]. Treatment interruption may be an option for patients who are not at high risk. These patients should be evaluated every 2 to 4 years, according to the Endocrine Society's guidelines [105], and therapy should be restarted if their risk of fracture increases or after a maximum of 5 years without treatment.

8.4 Denosumab DMAb

Inhibits bone resorption rapidly and can be reversed. When DMAb is stopped after a brief exposure (two years), BTMs temporarily rise from baseline, peaking approximately 12 months after the last dose (six months after a planned dose is skipped), and then returning to baseline [55]. After the last dose, BMD decreases immediately and returns to baseline about 18 months later [106]. Oral alendronate would preserve BMD gains when DMAb is discontinued following a brief exposure [107]. When DMAb is stopped after a longer exposure (>4 years), up-regulation of osteoclast genesis is stronger, which may explain why BPs are unable to fully preserve BMD [108].

The FREEDOM study was followed by a seven-year extension study that compared DMAb to a placebo for three years [109]. The rate of vertebral fracture among patients who stopped taking DMAb during FREEDOM or its extension was comparable to that of patients who were given a placebo [110]. There was a 3.4% increased risk of multiple vertebral fractures in patients who stopped taking DMAb compared to those who stopped taking placebo, with the highest risk occurring in patients who had previously experienced a vertebral fracture prior to or during treatment [110]. Numerous vertebral cracks were likewise

feebly anticipated by time off treatment and BMD misfortune while off treatment [110]. These data emphasize the necessity of continuing to take DMAb at the 6-month dosing interval without considering other options to prevent the loss of vertebral fracture protection and BMD. Treatment can continue for up to ten years, in contrast to BPs, and there is no plateau in spine, hip, or femoral neck BMD [109]. Compared to the first three years, DMAb's risk of nonvertebral fractures decreased further from years 4 to 10 [111]. The first treatment for osteoporosis that has improved over time has been this one. A low annual rate of new vertebral fractures (ranging from 0.90 percent to 1.86 percent) and nonvertebral fractures (ranging from 0.84 percent to 2.55%) remained stable for up to 10 years in patients receiving DMAb [109].

9. Predicting how likely a fracture will be over time: the significance of bone density and risk factors

Clinical applications of bone densitometry. [112] (2002 Ann Intern Med). In this article, guidelines for using bone density testing for osteoporosis screening are discussed. Independent of BMD, risk factors for hip fracture include age, maternal history of hip fracture (not kyphosis), conditions that increase the risk of falling, and serum oestradiol levels. Nomograms were created using femoral neck BMD and age data from the Study of Osteoporotic Fractures trial. White women had a five-year risk of hip and vertebral fractures, according to these nomograms. The 5-year fracture risks for women under 65 were extrapolated. The authors argue that risk factors like sex, weight, and race make it impossible to accurately predict BMD, despite the fact that risk factors like these are linked to BMD. Many experts believe that patients should be informed about their 5-year fracture risk and bone density. While the estimated fracture risk is more tangible and aids in clinical decision-making, patients struggle to comprehend the T-score.

II. Conclusion

There are currently and are being developed new treatment options for osteoporosis. They enable us to achieve greater gains in bone mass, more convenient medication regimens, and a more predictable decrease in fractures. We were able to re-evaluate the role of oestrogen in treating osteoporosis, preventing fractures, and balancing the risks and benefits to women's overall health with the assistance of new data. We are getting better at using bone density to predict fracture risk and assess bone mass with greater precision. The prevention of fractures and the quality of life will all rise significantly as a result of these advancements, both now and in the future.

Conflict Of Interest

All authors declare no conflicts of interest.

Authors Contribution

Authors have equally participated and shared every item of the work.

References

[1] Nguyen, Nguyen D., et al. "Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks." *Osteoporosis International* 19 (2008): 1431-1444.

[2] Cooper, Cyrus. "The crippling consequences of fractures and their impact on quality of life." *The American journal of medicine* 103.2 (1997): S12-S19.

[3] Ross, Philip D. "Osteoporosis: frequency, consequences, and risk factors." *Archives of internal medicine* 156.13 (1996): 1399-1411.

[4] Torgerson, David J., and Paul Dolan. "Advice given to patients with fractures: drug treatments that reduce fracture rate are underused after vertebral fractures." *BMJ: British Medical Journal* 318.7199 (1999): 1698.

[5] Pal, Badal. "Questionnaire survey of advice given to patients with fractures." *Bmj* 318.7182 (1999): 500-501.

[6] Epstein, S. "Postmenopausal osteoporosis: fracture consequences and treatment efficacy vary by skeletal site." *Aging Clinical and Experimental Research* 12 (2000): 330-341.

[7] Christiansen, C. "Consensus development conference: prophylaxis and treatment of osteoporosis." *Am J Med* 90 (1991): 107-110.

[8] Silva, Matthew J., Tony M. Keaveny, and Wilson C. Hayes. "Computed tomography-based finite element analysis predicts failure loads and fracture patterns for vertebral sections." *Journal of Orthopaedic Research* 16.3 (1998): 300-308.

[9] Kanis, John A., and F. A. Pitt. "Epidemiology of osteoporosis." *Bone* 13 (1992): S7-S15.

[10] MELTON III, L. JOSEPH, et al. "Epidemiology of vertebral fractures in women." *American journal of epidemiology* 129.5 (1989): 1000-1011.

[11] Seeley, Dana G., et al. "Which fractures are associated with low appendicular bone mass in elderly women?" *Annals of internal medicine* 115.11 (1991): 837-842.

[12] Sanders, K. M., et al. "The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study." *Journal of Bone and Mineral Research* 13.8 (1998): 1337-1342.

[13] Lauritzen, Jes Bruun. "Osteoporotic fractures–epidemiology, fall cascade, risk factors, and prevention." *Orthopaedic Issues in Osteoporosis* (2003): 171-190.

[14] Oden, A., et al. "Lifetime risk of hip fractures is underestimated." *Osteoporosis international* 8 (1998): 599-603.

[15] Farmer, Mary E., et al. "Race and sex differences in hip fracture incidence." *American journal of public health* 74.12 (1984): 1374-1380.

[16] Hagino, H., et al. "The incidence of fractures of the proximal femur and the distal radius in Tottori prefecture, Japan." *Archives of Orthopaedic and Trauma Surgery* 109 (1989): 43-44.

[17] Johnel, O., et al. "The apparent incidence of hip fracture in Europe: a study of national register sources." *Osteoporosis international* 2 (1992): 298-302.

[18] Gullberg, B., O. Johnell, and J. A. Kanis. "World-wide projections for hip fracture." *Osteoporosis international* 7 (1997): 407-413.

[19] Kanis, John A., et al. "Guidelines for diagnosis and management of osteoporosis." *Osteoporosis international* 7 (1997): 390-406.

[20] Block, J. E., and H. Stubbs. "Hip fracture-associated mortality reconsidered." *Calcified tissue international* 61.1 (1997): 84.

[21] Schürch, M-A., et al. "A prospective study on socioeconomic aspects of fracture of the proximal femur." *Journal of Bone and Mineral Research* 11.12 (1996): 1935-1942.

[22] Johnell, Olof. "The socioeconomic burden of fractures: today and in the 21st century." *The American journal of medicine*103.2 (1997): S20-S26.

[23] Jalovaara, Pekka, and Heikki Virkkunen. "Quality of life after primary hemiarthroplasty for femoral neck fracture: 6-year follow-up of 185 patients." *Acta Orthopaedica Scandinavica*62.3 (1991): 208-217.

[24] Cummings, Steven R., Dennis M. Black, and Susan M. Rubin. "Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women." *Archives of internal medicine* 149.11 (1989): 2445-2448.

[25] Chrischilles, E., T. Shireman, and R. Wallace. "Costs and health effects of osteoporotic fractures." *Bone* 15.4 (1994): 377-386.

[26] Phillips, Spencer, et al. "The direct medical costs of osteoporosis for American women aged 45 and older, 1986." *Bone* 9.5 (1988): 271-279.

[27] Greendale, Gail A., et al. "Late physical and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study." *Journal of the American Geriatrics Society* 43.9 (1995): 955-961.

[28] Center, Jacqueline R., et al. "Mortality after all major types of osteoporotic fracture in men and women: an observational study." *The Lancet* 353.9156 (1999): 878-882.

[29] Cooper, Cyrus, et al. "Population-based study of survival after osteoporotic fractures." *American journal of epidemiology*137.9 (1993): 1001-1005.

[30] Ross, Philip D. "Clinical consequences of vertebral fractures." *The American journal of medicine* 103.2 (1997): S30-S43.

[31] Nevitt, Michael C., et al. "The association of radiographically detected vertebral fractures with back pain and function: a prospective study." *Annals of internal medicine* 128.10 (1998): 793-800.

[32] Huang, Chun, Philip D. Ross, and Richard D. Wasnich. "Vertebral fracture and other predictors of physical impairment and health care utilization." *Archives of internal medicine*156.21 (1996): 2469-2475.

[33] Epstein, S. "Postmenopausal osteoporosis: fracture consequences and treatment efficacy vary by skeletal site." *Aging Clinical and Experimental Research* 12 (2000): 330-341.

[34] Ettinger, Bruce, et al. "Contribution of vertebral deformities to chronic back pain and disability." *Journal of Bone and Mineral Research* 7.4 (1992): 449-456.

[35] Frost, H. M. "Personal experience in managing acute compression fractures, their aftermath, and the bone pain syndrome, in osteoporosis." *Osteoporosis international* 8 (1998): 13-15.

[36] Cook, Deborah J., et al. "Quality of life issues in women with vertebral fractures due to osteoporosis." *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 36.6 (1993): 750-756.

[37] Cauley, J. A., et al. "Risk of mortality following clinical fractures." *JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE*. Vol. 8. No. 5. 2 MADISON AVENUE, LARCHMONT, NY 10538 USA: MARY ANN LIEBERT INC PUBL, 1999.

[38] Huang, Chun, et al. "Contributions of vertebral fractures to stature loss among elderly Japanese-American women in Hawaii." *Journal of Bone and Mineral Research* 11.3 (1996): 408-411.

[39] Leidig-Bruckner, G., et al. "Clinical grading of spinal osteoporosis: quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis." *Journal of Bone and Mineral Research* 12.4 (1997): 663-675.

[40] Gold, D. T. "The clinical impact of vertebral fractures: quality of life in women with osteoporosis." *Bone* 18.3 (1996): S185-S189.

[41] Melton, LJ 3rd, et al. "Secular trends in hip fracture incidence and recurrence." *Osteoporosis International* 20 (2009): 687-694.

[42] McClung, Michael R., et al. "Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study." *The Journal of Clinical Endocrinology & Metabolism* 89.10 (2004): 4879-4885.

[43] Doube, Alan. "Managing osteoporosis in older people with fractures needs to be taken as seriously as coronary artery disease." *BMJ* 318.7182 (1999): 477-478.

[44] Skedros, John G., et al. "The orthopedist as clinical densitometrist: Cost-and time-effectiveness." *AMERICAN JOURNAL OF ORTHOPEDICS-BELLE MEAD*- 36.1 (2007): 15.

[45] Schott, A. M., et al. "How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study." *Osteoporosis international* 8 (1998): 247-254.

[46] Marshall, Deborah, Olof Johnell, and Hans Wedel. "Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures." *Bmj* 312.7041 (1996): 1254-1259.

[47] Ross, P. D., et al. "Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women." *Osteoporosis International* 3 (1993): 120-126.

[48] Looker, A. C., et al. "Updated data on proximal femur bone mineral levels of US adults." *Osteoporosis international* 8 (1998): 468-490.

[49] Landsman, CM Klotzbuecher PD Ross PB, and TA Abbott Suffix III M. Berger. "ArticleTitle Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis." *J Bone Miner Res* 15 (2000): 721-739.

[50] Nevitt, M. C., et al. "Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures." *Bone* 25.5 (1999): 613-619.

[51] Ross, Philip D., et al. "Pre-existing fractures and bone mass predict vertebral fracture incidence in women." *Annals of internal medicine* 114.11 (1991): 919-923.

[52] Faulkner, K. G., et al. "Heel BMD and the NOF criteria predict fractures in both Caucasian and non-Caucasian women." *OSTEOPOROSIS INTERNATIONAL*. Vol. 11. SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING GU7 3DJ, SURREY, ENGLAND: SPRINGER-VERLAG LONDON LTD, 2000.

[53] Geusens, Piet, and Steven Boonen. "Risk assessment for osteoporosis using bone mineral density determination: a belgian perspective." *Journal of Clinical Densitometry* 1.4 (1998): 355-358.

[54] Brennan, N. J., and G. A. Caplan. "Attitudes to osteoporosis and hormone replacement therapy among elderly women." *Osteoporosis international* 9 (1999): 139-143.

[55] Guyatt, Gordon H. "Evidence-based management of patients with osteoporosis." *Journal of Clinical Densitometry* 1.4 (1998): 395-402.

[56] Seeman, Ego. "Osteoporosis: trials and tribulations." *The American journal of medicine* 103.2 (1997): S74-S89.

[57] Meunier, P. J. "Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials." *International Journal of Clinical Practice* 53.2 (1999): 122-129.

[58] Hochberg, Marc C., et al. "Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis." *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 42.6 (1999): 1246-1254.

[59] Riggs, B. Lawrence, et al. "Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis." *New England journal of medicine* 322.12 (1990): 802-809.

[60] Black, Dennis M., et al. "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures." *The Lancet* 348.9041 (1996): 1535-1541.

[61] Chapuy, Marie C., et al. "Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women." *BMJ: British Medical Journal* 308.6936 (1994): 1081.

[62] Ettinger, Bruce, et al. "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial." *Jama* 282.7 (1999): 637-645.

[63] Harris, Steven T., et al. "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial." *Jama* 282.14 (1999): 1344-1352.

[64] Reginster, J-Y., et al. "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis." *Osteoporosis international* 11 (2000): 83-91.

[65] Hillner, Bruce E., et al. "American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer." *Journal of Clinical Oncology* 21.21 (2003): 4042-4057.

[66] Miller, P. "Risedronate reduces hip fractures in patients with low femoral neck bone mineral density." *Arthritis Rheum* 42.9 (1999): S287-S295.

[67] Hochberg, Marc. "Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents." *Drugs & aging* 17 (2000): 317-330.

[68] Cummings, Steven R., et al. "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial." *Jama*280.24 (1998): 2077-2082.

[69] Liberman, U. A., et al. "II, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis." *N Engl J Med* 333.22: 1437-1443.

[70] Karpf, David B., et al. "Prevention of nonvertebral fractures by alendronate: a meta-analysis." *JaMa* 277.14 (1997): 1159-1164.

[71] Ensrud, K., et al. "Prevalent vertebral fractures predict hospitalization and mortality in older women: The fracture intervention trial (FIT)." *ARTHRITIS AND RHEUMATISM*. Vol. 41. No. 9. 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA: LIPPINCOTT WILLIAMS & WILKINS, 1998.

[72] Schnitzer, T. "Bone HG. Crepaldi G. Adami S. McClung M. Kiel D. et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group." *Aging (Milano)* 12 (2000): 1-12.

[73] Lips, Paul, et al. "Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial." *Annals of Internal Medicine* 124.4 (1996): 400-406.

[74] Dawson-Hughes, Bess, et al. "Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older." *New England Journal of Medicine* 337.10 (1997): 670-676.

[75] Riggs, B. Lawrence, et al. "Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women." *Journal of Bone and Mineral Research* 13.2 (1998): 168-174.

[76] Cosman, Felicia, Steven Cummings, and Robert Lindsay. "Guest Editorial: How Long Should Patients with Osteoporosis Be Treated with Bisphosphonates?" *Journal of Women's Health & Gender-Based Medicine* 9.2 (2000): 81-84.

[77] Tonino, Richard P., et al. "Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women." *The Journal of Clinical Endocrinology & Metabolism* 85.9 (2000): 3109-3115.

[78] Mashiba, Tasuku, et al. "Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib." *Journal of Bone and Mineral Research* 15.4 (2000): 613-620.

[79] Balena, R., et al. "The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates." *The Journal of clinical investigation* 92.6 (1993): 2577-2586.

[80] Weinstein, Robert S. "Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity." *Bone* 46.3 (2010): 564-570.

[81] Reid, Ian R., et al. "Intravenous zoledronic acid in postmenopausal women with low bone mineral density." *New England Journal of Medicine* 346.9 (2002): 653-661.

[82] Neer, Robert M., et al. "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis." *New England journal of medicine* 344.19 (2001): 1434-1441.

[83] Finkelstein, Joel S., et al. "The effects of parathyroid hormone, alendronate, or both in men with osteoporosis." *New England Journal of Medicine* 349.13 (2003): 1216-1226.

[84] Finkelstein, Joel S., et al. "The effects of parathyroid hormone, alendronate, or both in men with osteoporosis." *New England Journal of Medicine* 349.13 (2003): 1216-1226.

[85] Orwoll, ESWH SCHEELES, et al. "The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis." *Journal of bone and mineral research* 18.1 (2003): 9-17.

[86] Abramowicz, Mark. "Teriparatide (Forteo) for osteoporosis." *Medical Letter on Drugs and Therapeutics* 45.1149 (2003): 9-9.

[87] Rossouw, Jacques E., et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial." *Jama* 288.3 (2002): 321-333.

[88] Grady, Deborah, et al. "Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)." *Jama* 288.1 (2002): 49-57.

[89] Grady, Deborah, et al. "Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)." *Jama* 288.1 (2002): 49-57.

[90] Lindsay, Robert, et al. "Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women." *Jama* 287.20 (2002): 2668-2676.

[91] Recker, Robert R., et al. "The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial." *Annals of internal medicine* 130.11 (1999): 897-904.

[92] Ferrari, Serge, et al. "Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment." *Journal of Bone and Mineral Research* 34.6 (2019): 1033-1040.

[93] Cummings, Steven R., et al. "Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis." *Journal of Bone and Mineral Research* 32.1 (2017): 3-10.

[94] Michael Lewiecki, E. "Osteoporosis: treat-to-target." *Current Osteoporosis Reports* 15 (2017): 103-109.

[95] Bouxsein, Mary L., et al. "Change in bone density and reduction in fracture risk: a meta-regression of published trials." *Journal of Bone and Mineral Research* 34.4 (2019): 632-642.

[96] Dennison, Elaine M., et al. "Fracture risk following intermission of osteoporosis therapy." *Osteoporosis International* 30 (2019): 1733-1743.

[97] Eastell, Richard, et al. "Effect of stopping risedronate after long-term treatment on bone turnover." *The Journal of Clinical Endocrinology & Metabolism* 96.11 (2011): 3367-3373.

[98] Black, Dennis M., et al. "Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial." *Jama* 296.24 (2006): 2927-2938.

[99] Brown, Jacques P., et al. "Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays." *Canadian Family Physician* 60.4 (2014): 324-333.

[100] Black, Dennis M., et al. "The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)." *Journal of bone and mineral research* 27.2 (2012): 243-254.

[101] Black, Dennis M., et al. "The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)." *Journal of Bone and Mineral Research* 30.5 (2015): 934-944.

[102] Lyles, Kenneth W., et al. "Zoledronic acid and clinical fractures and mortality after hip fracture." *New England Journal of Medicine* 357.18 (2007): 1799-1809.

[103] Adler, Robert A., et al. "Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research." *Journal of Bone and Mineral Research* 31.1 (2016): 16-35.

[104] Miller, P. D., et al. "Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates." *Osteoporosis International* 31 (2020): 181-191.

[105] Eastell, Richard, et al. "Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline." *The Journal of Clinical Endocrinology & Metabolism* 104.5 (2019): 1595-1622.

[106] Bone, Henry G., et al. "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass." *The Journal of Clinical Endocrinology & Metabolism* 96.4 (2011): 972-980.

[107] Freemantle, N., et al. "Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women." *Osteoporosis International* 23 (2012): 317-326.

[108] Sølling, Anne Sophie, Torben Harsløf, and Bente Langdahl. "Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial." *Journal of Bone and Mineral Research* 35.10 (2020): 1858-1870.

[109] Bone, Henry G., et al. "10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension." *The lancet Diabetes & endocrinology* 5.7 (2017): 513-523.

[110] Cummings, Steven R., et al. "Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension." *Journal of Bone and Mineral Research* 33.2 (2018): 190-198.

[111] Ferrari, Serge, et al. "Further nonvertebral fracture reduction beyond 3 years for up to 10 years of denosumab treatment." *The Journal of Clinical Endocrinology & Metabolism* 104.8 (2019): 3450-3461.

[112] Bates, David W., Dennis M. Black, and Steven R. Cummings. "Clinical use of bone densitometry: clinical applications." *Jama*288.15 (2002): 1898-1900.